FDA Approves U.S. Product Labeling Update for Sprycel

09 Aug 2013 2:15 PM | Lori Aubrey (Administrator)

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase

Data added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options

View complete update on our Package and Labeling Updates Page

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software